Effect of the early rehabilitation treatment on the neurologic function in patients with different ischemic stroke TOAST subtypes

目的本研究旨在阐述不同急性卒中治疗Org10172(TrIAl Of Org10172 In ACuTE STrOkE TrEATMEnT,TOAST)分型脑梗死患者早期康复治疗的效果及其对神经功能恢复的影响。方法入选脑梗死患者共361例。按TOAST分型:大动脉粥样硬化型(lVA),心源性栓塞型(CE),小动脉闭塞性卒中和腔隙性梗死型(lACI),其它原因及不明原因型(SOd&Sud)。各亚型患者再分为早期康复治疗组及未干预组,记录患者,治疗1月后及随访6月后的美国国立卫生院卒中神经功能缺损评分量表(nATIOnAl InSTITuTES Of HEAlTH STrOkE SCAlE,nIHSS),bArTHEl IndEX评分及rAnkIn评分。结果入院时,腔隙性梗死型患者bArTHEl IndEX评分明显高于心源性栓塞型患者。发病6个月后,心源性栓塞型和大动脉粥样硬化型患者康复治疗组bArTHEl IndEX评分较未干预组高。结论早期康复治疗可用于脑梗死的治疗,特别是TOAST分型中的心源性栓塞型和大动脉粥样硬化型患者,对远期神经功能的恢复起到良好效果。Objective To clarify the prognostic differences of the early rehabilitation treatment method among different ischemic stroke subtypes.Methods 361 patients with acute ischemic stroke were collected,and were assessed with the Trial of Org 10172 in Acute Stroke Treatment( TOAST) classification: large- vessel atherothrombotic( LVA),cardioembolic( CE),small- vessel and lacunar infarct( LACI) and Stroke of Other Determined Etiology & Stroke of undetermined cause( SOD&SUD).All the patients were divided into 2 groups: early rehabilitation group and control group.The prognostic factors were assessed by NIHSS,Barthel Index and Rankin at the 1 month and 6 month after rehabilitation treatment.Results On admission,Barthel Index scores of LACI patients were higher than those of CE patients.6 month after cerebral infarction onset,patients in rehabilitation groups of CE and LVA had higher Barthel Index scores than those in control group.Conclusion We should adopt rehabilitation measures in cerebral ischemic stroke,especially for CE and LVA patients,because proper rehabilitation treatment will result in excellent prognosis for long.国家自然科学基金青年项目(81400984); 福建省自然科学基金青年创新项目(2014D009

ストロー内液層の長さが凍結融解後の媒液の浸透圧に及ぼす影響（予報）

本研究では、胚を収容する液層の長さが凍結融解後の凍結媒液の浸透圧に与える影響について検討した。実験には、1.5Mエチレングリコール (EG)、1.5M EG ＋ 0.1Mショ糖 (Suc)、1.4Mグリセリン (Gly）、1.4M Gly ＋ 0.1M Suc の4種類の凍結媒液を用い、液層の長さを2、3、5および7cmの4段階とした。浸透圧は、凍結融解後の凍特媒液を2倍希釈して測定した。0.25mlプラスチックストローを使用し、4段階に分けた液層ごとにストローを用意した。測定結果では、Gly（702.2mOsm/kg) が最も低く、ついでEG (817.8mOsm/kg)、Gly＋Suc（985mOsm/kg)、EG＋Suc（855.4mOsm/kg) の順に高く、いずれの聞にも有意差（P＜0.01）が認められた。全ての媒液において液層の長さ7cmが有意に高く（P＜0.01)、液層の長さ2、3および5cmの各媒液間に顕著な差は認められなかった。また、Sucを含む媒液を用いると浸透圧の値が高くなり、その中でも液層部位2、3および5cmに比べ、7cmにおいて有意に高くなることが認められた。以上の結果から、Gly＋PBS、Gly＋Suc、EG＋Suc、EG＋PBSの4種類の凍結媒液において、胚を収納する液層の長さが7cm以上の場合は、融解後の胚生存率に影響する可能性が示唆された

Ten-year visual outcome and change in chorioretinal atrophy after intravitreal ranibizumab for macular neovascularization in pathologic myopia

PURPOSE: To investigate the 10-year visual outcome and chorioretinal atrophy after a single intravitreal ranibizumab injection (IVR) followed by a pro re nata (PRN) regimen for myopic macular neovascularization (mMNV) in pathologic myopia, and to identify the factors associated with 10-year best-corrected visual acuity (BCVA). METHODS: This retrospective observational study evaluated 26 consecutive treatment-naïve eyes (26 patients) with mMNV in pathologic myopia who underwent a single IVR followed by a PRN regimen of IVR and/or intravitreal aflibercept injection and observed over 10 years. We assessed changes in BCVA and morphological parameters, including the META-PM Study category as a chorioretinal atrophy index. RESULTS: The logarithm of the minimum angle of resolution BCVA changed from 0.36 (Snellen, 20/45) ± 0.39 to 0.39 (20/49) ± 0.36 over 10 years of observation. Compared to baseline, 1-year BCVA improved (P = 0.002), whereas 2-10-year BCVA was not significantly different. Total injection frequency was 3.8 ± 2.6. In none of the eyes, 10-year BCVA was 20/200 or less. Ten-year BCVA correlated with baseline BCVA (P = 0.01, r = 0.47). The META-PM Study category progressed in 60% of eyes. There were no drug-induced complications. CONCLUSIONS: BCVA in eyes with mMNV in pathologic myopia was maintained for 10 years after a single IVR followed by a PRN regimen without drug-induced complications. The META-PM Study category progressed in 60% of eyes, especially those with older baseline age. Early diagnosis and treatment of mMNV are essential to maintain good long-term BCVA

JUNO Sensitivity on Proton Decay p→νˉK+p\to \bar\nu K^+ Searches

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this paper, the potential on searching for proton decay in $p\to \bar\nu K^+$ mode with JUNO is investigated.The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits to suppress the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar\nu K^+$ is 36.9% with a background level of 0.2 events after 10 years of data taking. The estimated sensitivity based on 200 kton-years exposure is $9.6 \times 10^{33}$ years, competitive with the current best limits on the proton lifetime in this channel

JUNO sensitivity on proton decay p → ν K + searches*

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this study, the potential of searching for proton decay in the $p\to \bar{\nu} K^+$ mode with JUNO is investigated. The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits suppression of the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar{\nu} K^+$ is 36.9% ± 4.9% with a background level of $0.2\pm 0.05({\rm syst})\pm$$0.2({\rm stat})$ events after 10 years of data collection. The estimated sensitivity based on 200 kton-years of exposure is $9.6 \times 10^{33}$ years, which is competitive with the current best limits on the proton lifetime in this channel and complements the use of different detection technologies